



Last updated: February 2024

LICENSING PORTFOLIO

PRODUCT	FORM	STRENGTH	INDICATION	AVAILABILITY
Avatrombopag ^{New}	Tablet	20mg	Chronic immune thrombocytopenia	Q2-25 (ANDA) Q2-25 (EU)
Bempedoic Acid ^{New}	Tablet	180mg	Cardiovascular	Q3-25 (ANDA)
Bempedoic Acid/ Ezetimibe ^{New}	Tablet	180mg/10mg	Cardiovascular	Q3-25 (ANDA)
Idebenone ^{New}	Tablet	150mg	Optic neuropathy	Q3-25 (EU)
Zinc Sulphate ^{New}	Capsules	220mg	Immune Booster (FS)	Ready (EU)
Dexmedetomidine [†]	Solution for injection	100mcg/ml	Sedative	Dossier ready (US & EU)
Erdosteine	Effervescent tablets	300mg	COPD	Under development (EU)
Fosphenytoin	Concentrate for solution injection	75mg/ml	Antiepileptic	Dossier ready (EU)
Isosorbide mononitrate	SR tablets	30mg	Cardiovascular	Dossier ready (EU)
Nystatin	Oral suspension	100000 IU/ml	Antifungal	Dossier ready (EU)
Piperacillin/ Tazobactam	Powder for injection	2g/250mg 4g/500mg	Antibiotic	Ready (EU)
Tafluprost	Ophthalmic solution	0.0015%	Glaucoma	Dossier ready (EU)

*Vertically integrated. In-house API.

Products will not be supplied prior to expiry of relevant conflicting patents in the territory.

About Recipharm: Recipharm is a leading contract development and manufacturing organisation (CDMO) headquartered in Stockholm, Sweden. We operate development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and are continuing to grow and expand our offering for our customers.

Employing around 9,000 people, we are focused on supporting pharmaceutical companies with our full service offering, taking products from early development through to commercial production. For over 25 years we have been there for our clients throughout the entire product lifecycle, providing pharmaceutical expertise and managing complexity, time and time again.

Despite our growing global footprint, we conduct our business as we always have and continue to deliver value for money with each customer's needs firmly at the heart of all that we do. That's the Recipharm way.

For further information please contact:

Agatha Vazquez, Head of Business Development
agatha.vazquez@recipharm.com

[recipharm.com](https://www.recipharm.com)